沙利度胺联合CHOP方案治疗外周T细胞淋巴瘤的效果  

Effect of thalidomide combined with CHOP on patients with peripheral T-cell lymphoma

作　　者：段现良[1] 马丛丛 化静 Duan Xianliang;Ma Congcong;Hua Jing(Department of Hematology,Liaocheng People’s Hospital,Liaocehng 252000,China)

机构地区：[1]山东省聊城市人民医院血液科,252000

出　　处：《中国实用医刊》2020年第4期94-97,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨沙利度胺联合CHOP方案(环磷酰胺+表柔比星+长春新碱+泼尼松)治疗外周T细胞淋巴瘤的临床效果。方法选取2017年1月至2019年1月于聊城市人民医院接受治疗的外周T细胞淋巴瘤患者72例,按随机数字表法分为观察组(36例)与对照组(36例)。对照组采用CHOP方案治疗,观察组则在对照组基础上联合沙利度胺治疗。3周为一疗程,两组均连续治疗8个疗程。比较两组临床疗效与治疗前后的精氨酸酶1(Arg-1)、血管内皮生长因子(VEGF)、诱生型一氧化氮合酶(iNOS)水平及治疗期间的不良反应(胃肠道反应、肝损伤、骨髓抑制、神经毒性、脱发、皮疹)情况。结果治疗后,观察组总有效率(86.11%)高于对照组(63.89%),差异有统计学意义(P<0.05);治疗后,观察组Arg-1、VEGF、iNOS水平[(12.38±2.50)ng/ml、(20.11±10.02)pg/ml、(14.96±3.72)U/ml]低于对照组[(14.29±2.40)ng/ml、(32.72±10.43)pg/ml、(16.77±3.80)U/ml],差异有统计学意义(P<0.05);治疗期间,两组各项不良反应的发生率比较,差异未见统计学意义(P>0.05)。结论沙利度胺联合CHOP方案治疗外周T细胞淋巴瘤的临床效果显著,能有效降低Arg-1、VEGF、iNOS水平,且不会增加不良反应发生率。Objective To investigate the clinical efficacy of thalidomide combined with CHOP in the treatment of peripheral T-cell lymphoma.Methods A total of 72 patients with peripheral T-cell lymphoma treated in Liaocheng People’s Hospital from January 2017 to January 2019 were selected, and were divided into observation group (36 cases) and control group (36 cases) according to the random number table. CHOP was used in the control group, while thalidomide was used in the observation group. Three weeks was one course of treatment, and both groups received 8 consecutive courses of treatment. The clinical curative effect and levels of arginase 1 (Arg-1), vascular endothelial growth factor (VEGF), induce nitric oxide synthase (iNOS) compared before and after the two groups and the adverse reactions during the treatment of (gastrointestinal reaction, liver damage, bone marrow suppression, neurotoxicity, hair loss, skin rash) were compared between the two groups.Results After treatment, the total effective rate of observation group (86.11%) was higher than that of the control group (63.89%), the difference was statistically significant (P<0.05). After treatment, levels of Arg-1, VEGF and iNOS were (12.38±2.50) ng/ml, (20.11±10.02) pg/ml and (14.96±3.72) U/ml respectively in the observation group, lower than (14.29±2.40) ng/ml, (32.72±10.43) pg/ml and (16.77±3.80) U/ml in the control group , with significant differences (P<0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusions Thalidomide combined with CHOP has significant clinical effect in the treatment of peripheral T-cell lymphoma. It can effectively reduce Arg-1, VEGF and iNOS levels, without increasing the incidence of adverse reactions.

关 键 词：外周T细胞淋巴癌 CHOP方案 沙利度胺 

分 类 号：R733[医药卫生—肿瘤]